Dose-dependent urinary phenotype of inorganic arsenic methylation in mice with a focus on trivalent methylated metabolites

Toxicology Mechanisms and Methods

Volumn 21, Issue 9, 2011, Pages 649-655

  García Montalvo, Eliud A ^a   Valenzuela, Olga L ^a   Sánchez Pea, Luz C ^a   Albores, Arnulfo ^a   Del Razo, Luz M ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Arsenite; Disposition; Metabolism; Mouse

Indexed keywords

ARSENIC ACID; ARSENITE SODIUM; ORGANOARSENIC DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; FLUID INTAKE; IN VIVO STUDY; METABOLITE; METHYLATION; MOUSE; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; URINALYSIS;

ANIMALS; ARSENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; METHYLATION; MICE; MICE, INBRED C57BL;

MUS;

EID: 80054768008     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2011.603765     Document Type: Article

References (33)

1. Aposhian HV, Gurzau ES, Le XC, Gurzau A, Healy SM, Lu X, Ma M, Yip L, Zakharyan RA, Maiorino RM, Dart RC, Tircus MG, Gonzalez-Ramirez D, Morgan DL, Avram D, Aposhian MM. 2000. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem Res Toxicol 13:693-697 (Pubitemid 30663445)
2. ATSDR (Agency for Toxic Substances and Disease Registry). (2000). Toxicological Profle for Arsenic. US. Department of Health and Human Services.
3. Bae ON, Lim KM, Noh JY, Chung SM, Kim SH, Chung JH. 2009. Trivalent methylated arsenical-induced phosphatidylserine exposure and apoptosis in platelets may lead to increased thrombus formation. Toxicol Appl Pharmacol 239:144-153.
4. Crecelius EA. 1977. Changes in the chemical speciation of arsenic following ingestion by man. Environ Health Perspect 19:147-150 (Pubitemid 8182691)
5. Currier JM, Svoboda M, de Moraes DP, Matousek T, Dedina J, Stýblo M. 2011. Direct analysis of methylated trivalent arsenicals in mouse liver by hydride generation-cryotrapping-atomic absorption spectrometry. Chem Res Toxicol 24:478-480.
6. Del Razo LM, García-Vargas GG, Vargas H, Albores A, Gonsebatt ME, Montero R, Ostrosky-Wegman P, Kelsh M, Cebrián ME. 1997. Altered profle of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch Toxicol 71:211-217. (Pubitemid 27122875)
7. Del Razo LM, Styblo M, Cullen WR, Tomas DJ. 2001. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174:282-293. (Pubitemid 32747839)
8. Devesa V, Del Razo LM, Adai B, Drobná Z, Waters SB, Hughes MF, Stýblo M, Tomas DJ. 2004. Comprehensive analysis of arsenic metabolites by pH-specifc hydride generation atomic absorption spectrometry. J Anal Atom Spectrom 19:1460-1467.
9. Fängström B, Hamadani J, Nermell B, Grandér M, Palm B, Vahter M. 2009. Impaired arsenic metabolism in children during weaning. Toxicol Appl Pharmacol 239:208-214.
10. Farago ME, Kavanagh P. 1999. Proportions of Arsenic Species in Human urine. In: Chappell WR, Abernathy CO, Calderon RL, ed. Arsenic Exposure and Health Efects. Elsevier Sciences B.V. 325-334.
11. Gong Z, Lu X, Cullen WR, Le XC. 2001. Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrom 16:1409-1413. (Pubitemid 34026211)
12. Hughes M, Kitchin K. (2006). Arsenic, oxidative stress and carcinogenesis. In: Singh K, ed., Oxidative Stress, Disease and Cancer. London: Imperial College press, 825-50.
13. Hughes MF, Kenyon EM. 1998. Dose-dependent efects on the disposition of monomethylarsonic acid and dimethylarsinic acid in the mouse after intravenous administration. J Toxicol Environ Health Part A 53:95-112.
14. Hughes ML, Carstensen B, Wilkinson JL, Weintraub RG. 2007. Angiographic diagnosis, prevalence and outcomes for left ventricular noncompaction in children with congenital cardiac disease. Cardiol Young 17:56-63 (Pubitemid 46322011)
15. Jiang G, Gong Z, Li X F, Cullen WR, Le XC. 2003. Interaction of trivalent arsenicals with metallothionein. Chem Res Toxicol 16:873-880. (Pubitemid 36899002)
16. Kaltreider RC, Davis AM, Lariviere JP, Hamilton JW. 2001. Arsenic alters the function of the glucocorticoid receptor as a transcription factor. Environ Health Perspect 109:245-251. (Pubitemid 32331515)
17. Kenyon EM, Del Razo LM, Hughes MF, Kitchin KT. 2005. An integrated pharmacokinetic and pharmacodynamic study of arsenite action 2. Heme oxygenase induction in mice. Toxicology 206:389-401. (Pubitemid 39601024)
18. Kitchin KT, Wallace K. 2008. Te role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J Inorg Biochem 102:532-539.
19. Le XC, Cullen WR, Reimer KJ. 1994. Speciation of arsenic compounds by HPLC with hydride generation atomic absorption spectrometry and inductively coupled plasma mass spectrometry detection. Talanta 41:495-502.
20. Le XC, Lu X, Ma M, Cullen WR, Aposhian HV, Zheng B. 2000. Speciation of key arsenic metabolic intermediates in human urine. Anal Chem 72:5172-5177.
21. Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. 2000. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ Health Perspect 108: 1015-1018.
22. Maitra R, Hamilton JW. 2005. Arsenite regulates cystic fbrosis trans-membrane conductance regulator and p-glycoprotein: Evidence of pathway independence. Cell Physiol Biochem 16:109-118. (Pubitemid 41197094)
23. Mandal BK, Ogra Y, Suzuki KT. 2001. Identifcation of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-afected areas in West Bengal, India. Chem Res Toxicol 14:371-378. (Pubitemid 32367470)
24. NOM-062-ZOO-1999: Norma Ofcial Mexicana "Especifcaciones técnicas para la Producción, Cuidado y Uso de los Animales de Laboratorio". (2001) Diario Ofcial del Gobierno Mexicano.
25. Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P. 2008. Analytical artefacts in the speciation of arsenic in clinical samples. Anal Chim Acta 607:83-91. (Pubitemid 50014947)
26. Soto-Reyes E, Del Razo LM, Valverde M, Rojas E. 2005. Role of the alkali labile sites, reactive oxygen species and antioxidants in DNA damage induced by methylated trivalent metabolites of inorganic arsenic. Biometals 18:493-506. (Pubitemid 41747094)
27. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Tomas DJ. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289-299. (Pubitemid 30660931)
28. Tomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M. 2007. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med (Maywood) 232:3-13. (Pubitemid 46089936)
29. Vahter M, Friberg L, Rahnster B, Nygren A, Nolinder P. 1986. Airborne arsenic and urinary excretion of metabolites of inorganic arsenic among smelter workers. Int Arch Occup Environ Health 57:79-91. (Pubitemid 16171438)
30. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, Del Razo LM. 2005. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250-254. (Pubitemid 40450653)
31. Valenzuela OL, Drobná Z, Hernández-Castellanos E, Sánchez-Peña LC, García-Vargas GG, Borja-Aburto VH, Stýblo M, Del Razo LM. 2009. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol Appl Pharmacol 239:200-207.
32. Xie R, Johnson W, Spayd S, Hall GS, Buckley B. 2006. Arsenic speciation analysis of human urine using ion exchange chromatography coupled to inductively coupled plasma mass spectrometry. Anal Chim Acta 578:186-194. (Pubitemid 44396928)
33. Walton FS, Harmon AW, Paul DS, Drobná Z, Patel YM, Styblo M. 2004. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: Possible mechanism of arsenic-induced diabetes. Toxicol Appl Pharmacol 198:424-433. (Pubitemid 38969972)